5 medical companies received 100 million yuan in financing within 3 days, and oncology and brain science attracted capital attention

On February 16, the People's Daily health client reviewed public information and found that in the past 3 days, a total of 5 medical companies have announced financing information of 100 million yuan, including three companies in the field of oncology.

Jingyu Medical's 300 million yuan D+ round of financing, the field of brain science is focused on by capital

On February 16, SceneRay announced that it had completed a RMB 300 million D+ round of financing, which was jointly led by Sequoia China and Hillhouse Ventures

Jingyu Medical is an innovative high-tech medical device company integrating R&D, production and sales of brain pacemakers, with complete independent intellectual property rights

Both Chen Xuanze, vice president of Sequoia China, and the person in charge of the Hillhouse Venture Capital project believe that the field of brain science has huge market prospects and potential, and industrial development is one of the areas that capital focuses on

Qinhao Pharmaceutical has raised hundreds of millions of yuan in Series B financing, and domestic innovative drugs need to focus on "firsts"

On February 14, Qinhao Pharmaceutical (Suzhou) Co.

This round of financing was led by Linkage Ventures, followed by Gandao Fund, Panyi Investment, Guohai Innovation Capital and other institutions.

Qinhao Pharmaceutical is a global innovative biopharmaceutical company, focusing on the research and development of original anti-tumor small molecule new drugs, headquartered in Suzhou Industrial Park

In the view of Sun Hangcheng, managing partner of Cheng Venture Capital, the current domestic innovative drug industry is developing rapidly, and the competition in the industry is becoming more and more fierce.

Ganevi Medical raised hundreds of millions of yuan in Series B financing, dedicated to precise minimally invasive and smart medical treatment for tumors

Also this week, Ganevi Medical, a manufacturer of minimally invasive tumor medical devices, announced the completion of a series B financing of several hundred million yuan.

This financing will be used for the company's investment in the sustainable development of precision minimally invasive and smart medical fields.

The person in charge of the Hangshi Asset Management Project said that Ganeve Medical focuses on the whole diagnosis and treatment process of minimally invasive tumor treatment, and has advanced technologies that are comparable to international brands in the four fields of tumor biopsy, intelligent interventional positioning, minimally invasive treatment and fine surgery, which is conducive to Change the current industry competition situation where foreign imported brands are monopolized

Langmai Medical Devices has raised 100 million yuan in financing, and there is still a large domestic alternative space in the field of minimally invasive spine

On February 15, Shanghai Langmai Medical Device Technology Co.

Langmai Medical focuses on the research and development and manufacture of products in the field of minimally invasive spine surgery

Xu Wei, a partner of Decheng Capital, analyzed this.

Saiyuan Bio has raised nearly 100 million yuan in financing, and iPSC technology has broad prospects in tumor immunotherapy

On February 16, Saiyuan Biotechnology (Hangzhou) Co.

The main business of Saiyuan Bio is to differentiate engineered pluripotent stem cells (iPSCs) into innate immune cells and develop universal cellular drugs

Hu Xuyu, managing partner of Jifeng Capital, said: "Saiyuan Bio has first-class basic scientific research capabilities and process R&D production capabilities.
We are very optimistic about the company's iPSC innate immune cell platform technology and off-the-shelf cell therapy in the future in tumors and autoimmune diseases.
application
.
”